Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Core Insights - Immix Biopharma, Inc. focuses on NK cell-based immunotherapy, aiming to innovate within the biotech sector [1] Company Overview - The company has been under analysis for nearly two years, with a specific emphasis on its immunotherapy approach [1] - The analyst has a PhD in biochemistry and extensive experience in evaluating clinical trials and biotech firms, indicating a strong foundation for assessing the company's potential [1] Industry Context - The article highlights the importance of understanding the science behind biotech investments, suggesting that due diligence is crucial for investors in this sector [1]